In the T-group, IIEF-EF (maximum score: 30) increased by 8. 4AE0.4 [95% CI: 7.7;9.1] at 10 years (p<0.0001). The improvement was statistically significant vs. previous year for 9 years and significant vs baseline throughout the observation time. In CTRL, IIEF-EF declined by INTRODUCTION AND OBJECTIVES: Functional outcomes after VTP, AS or RP for localized prostate cancer differ. We evaluated urinary incontinence (UI) and erectile dysfunction (ED) from 2 prospective randomized controlled trials (RCTs), including the impact of conversion to radical therapy (RT) in men undergoing VTP and AS by morbidity modelling.
INTRODUCTION AND OBJECTIVES: Functional outcomes after VTP, AS or RP for localized prostate cancer differ. We evaluated urinary incontinence (UI) and erectile dysfunction (ED) from 2 prospective randomized controlled trials (RCTs), including the impact of conversion to radical therapy (RT) in men undergoing VTP and AS by morbidity modelling.
METHODS: Toxicity data from PCM301, a RCT comparing VTP and AS was correlated with toxicity profiles from ProtecT, a RCT comparing active monitoring, RP and external-beam radiotherapy. In both RCTs, toxicity was prospectively defined for each treatment strategy. ED and UI rates after VTP and AS were obtained from the 7-year extended follow-up (FU) arm of PCM301, using MedDRA terms to define adverse events (Grade II or higher). From the RP and RT arms of ProtecT, the time-dependent rates of ED and UI were used for RP, as well as for PCM301 patients converting to RT after VTP or AS. Area under the curve analysis demonstrated the ratio of time integrated toxicity exposure.
RESULTS: From PCM301, a total of 413 subjects were included (VTP 206, AS 207). Percentage of patients with ED and UI, as a function of time, is presented in panels A and B, respectively. The VTP, AS and RP area under the curves to 60 months for ED are 5.87, 8.55 and 28.21, respectively. The ratio of the areas under the curves for VTP/AS and VTP/RP are 0.69 (95%CI: 0.04,0.91) and 0.25 (95%CI: 0.18,0.35), respectively. For UI, the areas under the curves were 1.49, 3.93 and 12.18 for VTP, AS and RP, respectively yielding ratios of 0.38 (95%CI: 0.25,0.53) and 0.12 (95%CI: 0.09,0.16) for VTP/AS and VTP/ RP, respectively. CONCLUSIONS: When conversion to RT is taken into account, men undergoing VTP as their initial therapy suffered lesser ED and UI compared to those who started with either RP or AS. This superior toxicity profile of VTP can largely be attributed to its lower rate of conversion to RT.
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PD25-02 CONSIDERATION OF PROPER CANDIDATES FOR SELF-EXPANDABLE COVERED METALLIC STENTS IN PROSTATIC OBSTRUCTION COMPARING PROSTATE CANCER AND BENIGN DISEASE CASES
Se Young Choi, Bumjin Lim, Jae Hyeon Han, Yoon Soo Kyung, Dong Hyeon An, Hwiwoo Kim, Wonchul Lee*, Han Kyu Chae, Jaehoon Lee, Wonseok Choi, Dalsan You, In Gab Jeong, Choung-Soo Kim, Seoul, Korea, Republic of INTRODUCTION AND OBJECTIVES: We evaluated the efficacy of self-expandable covered metallic stent in prostatic urethra comparing benign prostatic disease and prostate cancer (PC).
METHODS: We reviewed 42 cases of self-expandable covered metallic stents with barbs. The cohort was divided into two groups of non-PC and PC. Variables of uroflowmetry, residual urine volume, and International Prostate Symptoms Score (IPSS) with quality of life (QOL) and duration from the insertion to removal were surveyed. Logistic regression analysis was used to predict the early stent removal within 3 months.
